DK stock · Healthcare sector · Biotechnology
Company Logo

Ascendis Pharma A/S

ASNDNASDAQ

100.65

USD
-3.23
(-3.11%)
Market Closed
-12.14P/E
-11Forward P/E
-0.61P/E to S&P500
5.617BMarket CAP
- -Div Yield
Upcoming Earnings
8 Nov-14 Nov
Shares Short
8/31/22
7.97M
Short % of Float
- -
Short % of Shares Outs.
14.29%
% Held by Insiders
0.06%
% Held by Institutions
115.76%
Beta
0.65
PEG Ratio
10.68
52w. high/low
172.65/61.58
Avg. Daily Volume
0.43M
Return %
Stock
S&P 500
1 year
(39.17)
(16.94)
3 years
(3.95)
24.30
5 years
178.42
48.01
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23.81
14.75
21.79
11.92
42.00
19.60
76.99
38.28
140.15
59.58
183.98
92.00
178.71
109.36
137.40
61.58
Currency:
- -
- -
- -
- -
- -
- -
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
1.44
1.89
0.83
0.34
0.17
0.05
0.26
0.29
0.14
0.14
0.34
Earnings per share
- -
- -
- -
- -
- -
- -
0.12
0.38
(0.57)
(1.39)
(2.58)
(3.68)
(3.17)
(4.69)
(8.28)
(7.00)
(7.11)
FCF per share
- -
- -
- -
- -
- -
- -
(0.09)
0.47
(1.11)
(1.87)
(2.29)
(2.86)
(3.44)
(3.89)
(5.79)
(8.07)
(9.04)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
0.03
0.11
0.02
0.04
0.03
0.03
0.06
0.11
0.43
0.44
0.43
Book Value per sh.
- -
- -
- -
- -
- -
- -
0.14
0.58
2.70
5.06
6.65
5.57
6.82
12.84
16.57
16.13
14.29
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
11
11
17
24
27
34
41
47
51
55
55
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
(13.2)
(6.7)
(8.0)
(20.0)
(22.4)
(17.3)
(20.6)
(12.1)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.7)
(0.3)
(0.3)
(0.8)
(0.9)
(0.5)
(0.7)
(0.6)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
16
20
14
8
5
2
11
13
7
8
19
Operating margin
- -
- -
- -
- -
- -
- -
9.7%
25.9%
(85.7)%
(515.2)%
(1,583.2)%
(7,290.3)%
(1,462.6)%
(1,695.1)%
(4,755.1)%
(5,808.6)%
(3,796.5)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
0
0
1
1
1
1
1
7
9
15
17
Net profit (m)
- -
- -
- -
- -
- -
- -
1
4
(10)
(33)
(69)
(124)
(130)
(218)
(419)
(384)
(393)
Income tax rate
- -
- -
- -
- -
- -
- -
2.7%
13.3%
6.6%
1.9%
0.3%
0.4%
0.3%
0.1%
0.1%
0.1%
(0.0)%
Net profit margin
- -
- -
- -
- -
- -
- -
8.0%
20.0%
(69.1)%
(405.5)%
(1,487.3)%
(8,097.8)%
(1,229.5)%
(1,630.0)%
(6,025.5)%
(4,931.6)%
(3,135.6)%
Working capital (m)
- -
- -
- -
- -
- -
(4)
(3)
1
40
114
171
181
254
563
687
706
997
Long-term debt (m)
- -
- -
- -
- -
- -
0
- -
- -
- -
- -
- -
- -
- -
31
85
98
498
Equity (m)
- -
- -
- -
- -
- -
0
2
6
46
120
177
187
280
597
839
884
608
ROIC
- -
- -
- -
- -
- -
- -
81.6%
64.8%
(21.1)%
(27.4)%
(38.8)%
(66.1)%
(46.4)%
(34.5)%
(45.0)%
(38.6)%
(31.0)%
Return on capital
- -
- -
- -
- -
- -
- -
5.1%
17.7%
(17.6)%
(25.5)%
(36.2)%
(58.9)%
(40.9)%
(32.1)%
(42.6)%
(35.0)%
(28.3)%
Return on equity
- -
- -
- -
- -
- -
- -
80.3%
64.7%
(21.1)%
(27.4)%
(38.8)%
(66.2)%
(46.5)%
(36.5)%
(50.0)%
(43.4)%
(64.7)%
Plowback ratio
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Forex (EUR/USD)
- -
- -
- -
- -
- -
- -
1.319
1.375
1.210
1.086
1.051
1.200
1.147
1.121
1.221
1.137
1.059
Capital Structure
30 Jun · 2022 | Q2
All numbers in millions
Total liabilities
$ 719
Total assets
$ 1,327
Long-term debt
$ 498
Cash and equiv.
$ 672
Goodwill
$ - -
Retained earnings
$ (1,621)
Common stock
56
Enterprise Value
$ 5,443
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
598
719
682
Receivables
5
7
23
Inventory
- -
- -
75
Other
8
0
(127)
Current assets
611
740
806
Acc. Payable
28
22
59
Debt due
6
7
7
Other
14
24
34
Current liabilities
48
53
100
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
11.87%
145.46%
47.70%
Cash flow
50.76%
46.98%
(76.78)%
Earnings
(8.44)%
39.08%
52.85%
Dividends
- -
- -
- -
Book value
5.36%
52.16%
150.67%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
2
1
3
1
7
2021
1
1
1
5
8
2022
7
6
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(1.25)
(1.88)
(2.41)
(2.75)
(8.28)
2021
(1.15)
(2.45)
(1.47)
(1.94)
(7.00)
2022
(2.21)
(1.46)
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Jan Moeller Mikkelsen
Full-time employees:
639
City:
Hellerup
Address:
Tuborg Boulevard 5
IPO:
Jan 28, 2015
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Recent News